Aspira Women's Health Announces Publication Of Two OvaWatch Peer-Reviewed Manuscripts
Portfolio Pulse from Benzinga Newsdesk
Aspira Women's Health Inc. (NASDAQ:AWH) announced the publication of two peer-reviewed manuscripts supporting the use of its OvaWatch diagnostic tool for ovarian cancer risk assessment in women with adnexal masses. The studies, published in Frontiers of Medicine and Gynecologic Oncology, demonstrate OvaWatch's potential to reduce unnecessary surgeries and provide effective risk monitoring, potentially accelerating its adoption for patient management. The company's total addressable market for its ovarian cancer risk assessment tests, OvaSuite, is estimated at 2.0-3.0 million tests per year.
May 07, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of two peer-reviewed manuscripts supporting the efficacy of OvaWatch by Aspira Women's Health could significantly enhance the company's reputation and accelerate the adoption of OvaWatch, potentially increasing revenue from its OvaSuite portfolio.
The positive outcomes from these studies directly support the clinical utility and potential market adoption of OvaWatch, which is critical for Aspira's growth. Given the estimated addressable market of 2.0-3.0 million tests per year, these publications could significantly impact Aspira's market position and financial performance by encouraging clinicians to adopt OvaWatch for managing patients with adnexal masses, thereby driving up demand for the company's testing services.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100